There is an increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies coupled with demand for rapid diagnostics is the key driver accentuating the growth. For instance, the discovery of novel biomarkers, which has proven to be significant to improve the diagnosis of autoimmune diseases is also one of the major factor driving the autoimmune diseases diagnostic market. Autoimmune Disease Diagnostics Market holds huge number of players operating in the segment for years with expertise and experience.
Despite of all the driving factors for the autoimmune disease diagnostics market there are some restraints which are also slowing down this market such as, high rate of false results, slow turnaround time, lack of experience and many more. Various multi-national companies are coming forward to develop products especially for the autoimmune disease diagnosis segment to address the growing healthcare concerns regarding this disease. In terms of geography, the Americas led the global autoimmune disease diagnostics market and will continue to dominate the market in the coming years.
Growing public awareness for autoimmune disorders
Improved laboratory techniques and automation
Increase in partnerships between physicians and clinical laboratories
Rising incidences of the disease like Rheumatoid arthritis, Graves and Hashimoto's Thyroid Disease, lupus and type 1 diabetes
Slow turnaround time for autoimmune disease diagnostic test results, high frequency of false positive results and inadequacy of skilled healthcare professionals in developing countries are the factors which are slowing down this market.
The Global autoimmune disease diagnostics market has been segmented based on disease type that are Systemic Autoimmune Disease (Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis etc.) and Localized Autoimmune Disease(Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid etc.). The market is also segmented by Diagnostics type. Diagnostics type is also further classified as Immunofluorescence Assays (IFA), Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Dot Blot, Line Blot, Multiplex Immunoassay, Agglutination, Double Immune Diffusion, Counterimmunoelectrophoresis and many more.
Globally the autoimmune disease diagnostics market has been segmented based on geography as North America, Europe, Asia-Pacific, Middle East & Africa and South America.
Some of the key players in this market include:
The Global autoimmune disease diagnostics market is dominated by the leading vendors such as Abbott Laboratories, F.Hoffmann-La Roche, Novartis Ag, Sanofi-Aventis, Astrazeneca, Lycera, Pfizer Inc., Celgene Corporation and Bristol-Myers Squibb. The key vendors are focusing on the development and commercialization of multiplex tests to meet evolving consumer needs. Moreover, several companies are pursuing inorganic growth strategies to expand their presence in the market.
Market definition for the cardiac assist devices market, along with identification of key drivers and restraints for the market.
Market analysis for Global autoimmune disease diagnostics market, with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the global autoimmune disease diagnostics market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities and Challenges Analysis (Droc)
6.1 Market Drivers
6.1.1 Growing Public Awareness of Autoimmune Disease
6.1.2 Improved Laboratory Automation
6.1.3 Partnerships With Physicians and Clinical Laboratories
6.1.4 Technological Advancements
6.1.5 Expansion in Coverage Allowed by Patient Protection and Affordable Care Act
6.2 Market Restraints
6.2.1 Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results
6.2.2 High Frequency of False Positive Result
6.3.1 European Union Funded Research Projects
6.3.2 Aarda Initiatives
6.3.3 High Prevalence Rate of Autoimmune Disease
6.4.1 Shortage of Skilled Personnel
7. Market Segmentation
7.1 by Disease Type
7.1.1 Systemic Autoimmune Disease
22.214.171.124 Rheumatoid Arthritis
126.96.36.199 Systemic Lupus Erythematosus (Sle)
188.8.131.52 Multiple Sclerosis
7.1.2 Localized Autoimmune Disease
184.108.40.206 Inflammatory Bowel Disease
220.127.116.11 Type 1 Diabetes
7.1.3 by Diagnostics
18.104.22.168 Immunofluorescence Assays (Ifa)
22.214.171.124 Enzyme-Linked Immunosorbent Assay (Elisa)
126.96.36.199 Western Blotting
188.8.131.52 Dot Blot
184.108.40.206 Line Blot
220.127.116.11 Multiplex Immunoassay
18.104.22.168 Double Immune Diffusion
7.2 by Geography
7.2.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
7.2.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
7.2.5 South America
126.96.36.199 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaboration and Partnerships
8.3 New Product Launches
9. Company Profiles
9.1 F. Hoffmann-La Roche
9.2 Euroimmun Ag
9.3 Siemens Healthineers Inc.
9.5 Trinity Biotech
9.6 Thermo Fisher Scientific
9.7 Myriad Genetics
9.8 Abbott Laboratories
9.9 Beckman Coulter
9.10 Bio-Rad Laboratories
10. Future Outlook of the Market